Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(23):1783-1790; doi:10.1093/jnci/93.23.1783
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ozen, M.
Right arrow Articles by Ittmann, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ozen, M.
Right arrow Articles by Ittmann, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 23, 1783-1790, December 5, 2001
© 2001 Oxford University Press


ARTICLE

Role of Fibroblast Growth Factor Receptor Signaling in Prostate Cancer Cell Survival

Mustafa Ozen, Dipak Giri, Frederic Ropiquet, Alka Mansukhani, Michael Ittmann

Affiliations of authors: M. Ozen, D. Giri, F. Ropiquet, M. Ittmann, Department of Pathology, Baylor College of Medicine, Houston, TX, and Houston Department of Veterans Affairs Medical Center; A. Mansukhani, Department of Microbiology, New York University School of Medicine, NY.

Correspondence to: Michael Ittmann, M.D., Ph.D., Research Service, Houston Department of Veterans Affairs Medical Center, 2002 Holcombe Blvd., Houston, TX 77030 (e-mail: mittmann{at}bcm.tmc.edu).

Background: Expression of fibroblast growth factors (FGFs) is increased in a substantial fraction of human prostate cancers in vivo and in prostate cancer cell lines. Altered FGF signaling can potentially have a variety of effects, including stimulating cell proliferation and inhibiting cell death. To determine the biologic significance of altered FGF signaling in human prostate cancer, we disrupted signaling by expression of a dominant-negative (DN) FGF receptor in prostate cancer cell lines. Methods: PC-3, LNCaP, and DU145 prostate cancer cells were stably transfected with DN FGFR constructs, and LNCaP and DU145 cells were infected with a recombinant adenovirus expressing DN FGFR-1. The effect of DN FGFR-1 expression was assessed by colony-formation assays, cell proliferation assays, flow cytometry, and cytogenetic analysis. Key regulators involved in the G2-to-M cell cycle transition were assessed by western blotting to examine cyclin B1 expression and by in vitro kinase assay to assess cdc2 kinase activity. Results: Stable transfection of the DN FGFR-1 construct inhibited colony formation by more than 99% in all three cell lines. Infection of LNCaP and DU145 prostate cancer cells with adenovirus expressing DN FGFR-1 led to extensive cell death within 48 hours. Flow cytometry and cytogenetic analysis revealed that the DN FGFR-1 receptor led to arrest in the G2 phase of the cell cycle before cell death. Cyclin B1 accumulated in DN FGFR-1-infected LNCaP cells, but cdc2 kinase activity was decreased. Conclusions: These findings reveal an unexpected dependence of prostate cancer cells on FGF receptor signal transduction to traverse the G2/M checkpoint. The mechanism for the G2 arrest is not clear. Our results raise the possibility that FGF-signaling antagonists might enhance the cell death induced by other prostate cancer therapies.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
H. Fischer, N. Taylor, S. Allerstorfer, M. Grusch, G. Sonvilla, K. Holzmann, U. Setinek, L. Elbling, H. Cantonati, B. Grasl-Kraupp, et al.
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Mol. Cancer Ther., October 1, 2008; 7(10): 3408 - 3419.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
L. M. Cotton, M. K. O'Bryan, and B. T. Hinton
Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction
Endocr. Rev., April 1, 2008; 29(2): 193 - 216.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T.-C. Liu, T. Zhang, H. Fukuhara, T. Kuroda, T. Todo, X. Canron, A. Bikfalvi, R. L. Martuza, A. Kurtz, and S. D. Rabkin
Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors.
Clin. Cancer Res., November 15, 2006; 12(22): 6791 - 6799.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. R. K. Loeb, J. L. Harris, and C. S. Craik
Granzyme B Proteolyzes Receptors Important to Proliferation and Survival, Tipping the Balance toward Apoptosis
J. Biol. Chem., September 22, 2006; 281(38): 28326 - 28335.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Martinez-Torrecuadrada, G. Cifuentes, P. Lopez-Serra, P. Saenz, A. Martinez, and J. I. Casal
Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation
Clin. Cancer Res., September 1, 2005; 11(17): 6280 - 6290.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Ozen and M. Ittmann
Increased Expression and Activity of CDC25C Phosphatase and an Alternatively Spliced Variant in Prostate Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4701 - 4706.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
B Kwabi-Addo, M Ozen, and M Ittmann
The role of fibroblast growth factors and their receptors in prostate cancer
Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. A. Shain
Exogenous Fibroblast Growth Factors Maintain Viability, Promote Proliferation, and Suppress GADD45{alpha} and GAS6 Transcript Content of Prostate Cancer Cells Genetically Modified to Lack Endogenous FGF-2
Mol. Cancer Res., November 1, 2004; 2(11): 653 - 661.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Wang, D. W. Stockton, and M. Ittmann
The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Prostate Cancer Initiation and Progression
Clin. Cancer Res., September 15, 2004; 10(18): 6169 - 6178.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Kwabi-Addo, J. Wang, H. Erdem, A. Vaid, P. Castro, G. Ayala, and M. Ittmann
The Expression of Sprouty1, an Inhibitor of Fibroblast Growth Factor Signal Transduction, Is Decreased in Human Prostate Cancer
Cancer Res., July 15, 2004; 64(14): 4728 - 4735.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. W. Freeman, R. D. Gangula, B. E. Welm, M. Ozen, B. A. Foster, J. M. Rosen, M. Ittmann, N. M. Greenberg, and D. M. Spencer
Conditional Activation of Fibroblast Growth Factor Receptor (FGFR) 1, but not FGFR2, in Prostate Cancer Cells Leads to Increased Osteopontin Induction, Extracellular Signal-regulated Kinase Activation, and in Vivo Proliferation
Cancer Res., October 1, 2003; 63(19): 6237 - 6243.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Polnaszek, B. Kwabi-Addo, L. E. Peterson, M. Ozen, N. M. Greenberg, S. Ortega, C. Basilico, and M. Ittmann
Fibroblast Growth Factor 2 Promotes Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer
Cancer Res., September 15, 2003; 63(18): 5754 - 5760.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.